Intacape

Intacape

capecitabine

Manufacturer:

Intas Pharmaceuticals

Distributor:

Alliance Pharma
Concise Prescribing Info
Contents
Capecitabine
Indications/Uses
Metastatic breast cancer resistant after failure of a taxane & an anthracycline-containing chemotherapy regimen. As single agent for adjuvant treatment in patients w/ Dukes' C colon cancer. Metastatic colorectal cancer. 1st-line treatment of advanced gastric cancer in combination w/ a platinum-based regimen.
Dosage/Direction for Use
Breast & colorectal cancer 1,000-1,250 mg/m2 bid (morning & evening) for 2 wk followed by a 1 wk rest period given as 3-wk cycle. Total dose: 2,000-2,500 mg/m2 daily. Gastric cancer 800-1,000 mg/m2/day bid for 2 wk followed by a 1 wk rest period given as a 3-wk cycle or 625 mg/m2/day bid continuous 21-day.
Administration
Should be taken with food: Take w/in 30 min after meals.
Contraindications
Hypersensitivity to capecitabine, 5-fluorouracil. Known dihydropyridine dehydrogenase deficiency. Severe renal impairment (CrCl <30 mL/min).
Special Precautions
Hepatic & renal impairment. Pregnancy & lactation. Childn <18 yr. Elderly.
Adverse Reactions
Hand-&-foot syndrome, diarrhea, nausea, vomiting, stomatitis.
Drug Interactions
Antacids, anticoagulants, phenytoin, leucovorin.
ATC Classification
L01BC06 - capecitabine ; Belongs to the class of antimetabolites, pyrimidine analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Intacape tab 500 mg
Packing/Price
12 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in